Annual report
4272.TEDINET S100TTFJ
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥201.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥198.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥184.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥173.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥175.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥7.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥21.5bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥12.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.2bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥21.0bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.8bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥4.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥15.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥363.2bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥322.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥315.5bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥294.5bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥278.5bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥92.6bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥67.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥270.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥255.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥246.4bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥228.3bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥210.0bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥56.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥48.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥64.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥47.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥46.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥23.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥20.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥24.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥27.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥19.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥15.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥3.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥8.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥13.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥24.8 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.36 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.7 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.62 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.25 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥24.79 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥89.33 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥101.65 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.61 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥74.23 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,625.18 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,532.35 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,459.06 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,332.06 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,225.71 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 74.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.8% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.2% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 1.6% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,902 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,782 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,703 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,664 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 5,847 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥120.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥128.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥124.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥115.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥106.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥3.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥10.5bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥4.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.2bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥16.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥967m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥15.5bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | −¥666m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥12.6bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥12.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥261.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥237.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥236.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥230.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥215.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥76.5bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥52.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥185.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥185.2bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥184.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥180.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥160.8bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥21.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥16.2bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-4.02 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.33 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.63 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥132.38 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.01 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥45 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,116.51 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,117.38 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,098.36 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,056.38 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥941.59 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 70.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.0% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.8% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 170,503,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 170,503,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 170,503,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 177,503,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 177,503,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,419 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 2,391 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 2,398 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 2,401 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 2,069 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 86
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥903m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥498m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥170m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥170m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥71.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥8.3bn |
| Fine Chemicals Business Unitreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥7.8bn |
| Fine Chemicals Business Unitreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.6bn |
| Fine Chemicals Business Unitreportable segment | employees | at 2024-03-31 | 1317 pure |
| Fine Chemicals Business Unitreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥57.2bn |
| Fine Chemicals Business Unitreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥57.1bn |
| Fine Chemicals Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥169m |
| Fine Chemicals Business Unitreportable segment | segment assets | at 2024-03-31 | ¥82.6bn |
| Fine Chemicals Business Unitreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.2bn |
| Life Science Business Unitreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥3.9bn |
| Life Science Business Unitreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Life Science Business Unitreportable segment | employees | at 2024-03-31 | 953 pure |
| Life Science Business Unitreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥63.5bn |
| Life Science Business Unitreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥63.5bn |
| Life Science Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| Life Science Business Unitreportable segment | segment assets | at 2024-03-31 | ¥84.8bn |
| Life Science Business Unitreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Mobility And Imaging Business Unitreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥6.8bn |
| Mobility And Imaging Business Unitreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥7.0bn |
| Mobility And Imaging Business Unitreportable segment | employees | at 2024-03-31 | 3388 pure |
| Mobility And Imaging Business Unitreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥81.2bn |
| Mobility And Imaging Business Unitreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥81.2bn |
| Mobility And Imaging Business Unitreportable segment | segment assets | at 2024-03-31 | ¥124.2bn |
| Mobility And Imaging Business Unitreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥8.0bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥18.4bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥13.4bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥202.0bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥201.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥170m |
| —segment total | segment assets | at 2024-03-31 | ¥291.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥18.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥202.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥201.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥170m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥291.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥15.6bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥368m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥480m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥164m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥164m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥50.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥7.6bn |
| Fine Chemicals Business Unitreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥4.8bn |
| Fine Chemicals Business Unitreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Fine Chemicals Business Unitreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥64.2bn |
| Fine Chemicals Business Unitreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥64.0bn |
| Fine Chemicals Business Unitreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥163m |
| Fine Chemicals Business Unitreportable segment | segment assets | at 2023-03-31 | ¥78.2bn |
| Fine Chemicals Business Unitreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥10.2bn |
| Life Science Business Unitreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.6bn |
| Life Science Business Unitreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.6bn |
| Life Science Business Unitreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥62.5bn |
| Life Science Business Unitreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥62.5bn |
| Life Science Business Unitreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥0 |
| Life Science Business Unitreportable segment | segment assets | at 2023-03-31 | ¥83.7bn |
| Life Science Business Unitreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥10.7bn |
| Mobility And Imaging Business Unitreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥4.6bn |
| Mobility And Imaging Business Unitreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥7.0bn |
| Mobility And Imaging Business Unitreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥71.9bn |
| Mobility And Imaging Business Unitreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥71.9bn |
| Mobility And Imaging Business Unitreportable segment | segment assets | at 2023-03-31 | ¥110.5bn |
| Mobility And Imaging Business Unitreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥8.2bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥12.1bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥13.2bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥198.5bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥198.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥164m |
| —segment total | segment assets | at 2023-03-31 | ¥272.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥29.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥13.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥198.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥198.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥164m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥272.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥29.1bn |
| Fine Chemicals Business Unitreportable segment | employees | at 2024-03-31 | 668 pure |
| Life Science Business Unitreportable segment | employees | at 2024-03-31 | 901 pure |
| Mobility And Imaging Business Unitreportable segment | employees | at 2024-03-31 | 608 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,046
| Item | Context | Value | Unit |
|---|---|---|---|
| Net assets (5-year summary) | CurrentYearInstant | 270548000000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant | 278496000000 | JPY |
| Total assets (5-year summary) | Prior3YearInstant | 294535000000 | JPY |
| Total assets (5-year summary) | Prior2YearInstant | 315459000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 322858000000 | JPY |
| Total assets (5-year summary) | CurrentYearInstant | 363173000000 | JPY |
| Net assets per share (5-year summary) | Prior4YearInstant | 1225.71 | |
| Net assets per share (5-year summary) | Prior3YearInstant | 1332.06 | |
| Net assets per share (5-year summary) | Prior2YearInstant | 1459.06 | |
| Net assets per share (5-year summary) | Prior1YearInstant | 1532.35 | |
| Net assets per share (5-year summary) | CurrentYearInstant | 1625.18 | |
| Basic earnings loss per share (5-year summary) | Prior4YearDuration | 74.25 | |
| Basic earnings loss per share (5-year summary) | Prior3YearDuration | 73.62 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration | 101.70 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 89.36 | |
| Basic earnings loss per share (5-year summary) | CurrentYearDuration | 24.80 | |
| Diluted earnings per share (5-year summary) | Prior4YearDuration | 74.23 | |
| Diluted earnings per share (5-year summary) | Prior3YearDuration | 73.61 | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration | 101.65 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 89.33 | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration | 24.79 | |
| Equity to asset ratio (5-year summary) | Prior4YearInstant | 0.752 | |
| Equity to asset ratio (5-year summary) | Prior3YearInstant | 0.772 | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant | 0.778 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.787 | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant | 0.742 | |
| Rate of return on equity (5-year summary) | Prior4YearDuration | 0.060 | |
| Rate of return on equity (5-year summary) | Prior3YearDuration | 0.058 | |
| Rate of return on equity (5-year summary) | Prior2YearDuration | 0.073 | |
| Rate of return on equity (5-year summary) | Prior1YearDuration | 0.060 | |
| Rate of return on equity (5-year summary) | CurrentYearDuration | 0.016 | |
| Price earnings ratio (5-year summary) | Prior4YearDuration | 13.4 | |
| Price earnings ratio (5-year summary) | Prior3YearDuration | 14.5 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration | 11.4 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration | 13.3 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration | 52.7 | |
| Net cash provided by used in operating activities (5-year summary) | Prior4YearDuration | 27281000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior3YearDuration | 24408000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration | 23141000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 20039000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration | 23242000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration | -17543000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration | -17606000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration | -10641000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -15158000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration | -19409000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration | -13894000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration | -8402000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration | -11090000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -7950000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |